Understanding CYP27B1: Potential Drug Target and Biomarker (G1594)

Target Name: CYP27B1

NCBI ID: G1594

CYP27B1

Understanding CYP27B1: Potential Drug Target and Biomarker

CYP27B1, also known as CYP27B or CYP27, is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the CYP27 family of proteins, which are involved in the detoxification and metabolism of a wide variety of drugs. One of the most interesting aspects of CYP27B1 is its potential as a drug target or biomarker.

CYP27B1 functions as a transmembrane protein that is involved in the transport of a variety of molecules across the blood-brain barrier. This includes drugs that are used to treat various neurological and psychiatric disorders, such as depression, anxiety, and schizophrenia. CYP27B1 is also involved in the detoxification of many of these drugs, which is important for their safe use.

One of the reasons why CYP27B1 is being targeted as a drug target is its role in the metabolism of many drugs. CYP27B1 is known to be involved in the metabolism of a wide variety of drugs, including many statins, which are used to treat high cholesterol. By modulating the levels of these drugs in the body, CYP27B1 can improve their effectiveness and reduce the risk of side effects.

Another reason why CYP27B1 is being targeted as a drug target is its role in the development of certain psychiatric disorders. Studies have shown that individuals with certain genetic variations in the CYP27B1 gene are at increased risk for the development of certain psychiatric disorders, such as depression and anxiety. By targeting this protein, researchers hope to develop new treatments for these disorders that can be tailored to individual genetic profiles.

In addition to its potential as a drug target, CYP27B1 is also being studied as a potential biomarker for certain psychiatric disorders. The CYP27B1 protein is expressed in many different tissues throughout the body, including the brain, and can be used as a diagnostic marker for certain psychiatric disorders. For example, researchers have used CYP27B1 to diagnose individuals with depression and anxiety disorders.

Overall, CYP27B1 is a protein that has significant implications for the development of new treatments for various psychiatric and neurological disorders. As research continues to advance, it is likely that we will learn more about the full range of functions and potential uses of this protein.

Protein Name: Cytochrome P450 Family 27 Subfamily B Member 1

Functions: A cytochrome P450 monooxygenase involved in vitamin D metabolism and in calcium and phosphorus homeostasis. Catalyzes the rate-limiting step in the activation of vitamin D in the kidney, namely the hydroxylation of 25-hydroxyvitamin D3/calcidiol at the C1alpha-position to form the hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3/calcitriol that acts via the vitamin D receptor (VDR) (PubMed:10518789, PubMed:9486994, PubMed:22862690, PubMed:10566658, PubMed:12050193). Has 1alpha-hydroxylase activity on vitamin D intermediates of the CYP24A1-mediated inactivation pathway (PubMed:10518789, PubMed:22862690). Converts 24R,25-dihydroxyvitamin D3/secalciferol to 1-alpha,24,25-trihydroxyvitamin D3, an active ligand of VDR. Also active on 25-hydroxyvitamin D2 (PubMed:10518789). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via FDXR/adrenodoxin reductase and FDX1/adrenodoxin (PubMed:22862690)

The "CYP27B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP27B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets